Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

[1] Choueiri TK(2017)Systemic therapy for metastatic renal-cell carcinoma N. Engl. J. Med. 376 354-366

[2] Motzer RJ(2017)Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology J. Natl Compr. Canc. Netw. 15 804-834

[3] Motzer RJ(2016)Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy Cancer Treat. Rev. 50 109-117

[4] Calvo E(2015)Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting Urol. Oncol. 33 538-545

[5] Schmidinger M(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N. Engl. J. Med. 373 1803-1813

[6] Heng DY(2015)Cabozantinib versus everolimus in advanced renal-cell carcinoma N. Engl. J. Med. 373 1814-1823

[7] Grunwald V(2016)Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial The Lancet Oncology 17 917-927

[8] Escudier B(2015)Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Lancet Oncol. 16 1473-1482

[9] de Velasco G(2017)Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma Curr. Oncol. Rep. 19 2298-2308

[10] Hamieh L(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 10 228-247

[1] Choueiri TK(2017)Systemic therapy for metastatic renal-cell carcinoma N. Engl. J. Med. 376 354-366

[2] Motzer RJ(2017)Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology J. Natl Compr. Canc. Netw. 15 804-834

[3] Motzer RJ(2016)Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy Cancer Treat. Rev. 50 109-117

[4] Calvo E(2015)Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting Urol. Oncol. 33 538-545

[5] Schmidinger M(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N. Engl. J. Med. 373 1803-1813

[6] Heng DY(2015)Cabozantinib versus everolimus in advanced renal-cell carcinoma N. Engl. J. Med. 373 1814-1823

[7] Grunwald V(2016)Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial The Lancet Oncology 17 917-927

[8] Escudier B(2015)Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Lancet Oncol. 16 1473-1482

[9] de Velasco G(2017)Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma Curr. Oncol. Rep. 19 2298-2308

[10] Hamieh L(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 10 228-247